CBX1 and Oral ulcer: Thus, we propose CBX as a therapeutic agent in OCVM, which is a non-specific, broadly-acting connexin inhibitor, extensively used to study connexin function in vitro and in vivo.[48, 49] CBX has been clinically approved and widely used for treating gastropeptic, esophageal, and oral ulcers for more than a decade [50].